ACELRX PHARMACEUTICALS, INC. (NASDAQ:ACRX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 2, 2017, Timothy E. Morris, Chief Financial Officer and Head of Business Development of AcelRx Pharmaceuticals, Inc. (the “Company”), notified the Company of his resignation from all positions with the Company effective immediately. In connection with Mr. Morris’ resignation, Vincent J. Angotti, the Company’s Chief Executive Officer, has been appointed to act as interim Chief Financial Officer of the Company.

About ACELRX PHARMACEUTICALS, INC. (NASDAQ:ACRX)

AcelRx Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain. Its lead product candidates include ARX-04, Zalviso, which utilize sublingual sufentanil, delivered through a non-invasive route of administration, and ARX-03. ARX-04 is meant for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in medically supervised settings. Zalviso is meant for the management of moderate-to-severe acute pain in hospitalized adult patients. ARX-03 provides mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician’s office. It also includes ARX-02, which is meant for the treatment of patients who suffer from breakthrough pain (BTP) due to cancer.

ACELRX PHARMACEUTICALS, INC. (NASDAQ:ACRX) Recent Trading Information

ACELRX PHARMACEUTICALS, INC. (NASDAQ:ACRX) closed its last trading session up +0.15 at 2.65 with 161,798 shares trading hands.